Lupin Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Record margins, raised US guidance: EBITDA margins hit a 5-year high of 24.3% while US revenue also reached a 5-year peak, prompting management to lift FY25 US growth guidance to double digits from high single digits.
• The pipeline is pivoting to complexity: Over 50% of the 30+ ANDAs planned for the next two years will be complex products, and Tolvaptan alone is expected to be the major contributor in H1 FY26.
• India business is a steady compounder: India Formulations grew 9.1% for 9M, outpacing the IPM, with chronic therapies leading the charge and the Huminsulin acquisition adding heft to the diabetes portfolio.
• Adjacencies are a margin drag with a payoff promise: Losses from newer adjacencies are shaving roughly two percentage points off margins, but management expects them to turn positive over the next three years.
• What to watch next quarter: The Mirabegron patent decision in Q1 FY26, the Q4 R&D spend spike as five nasal sprays get filed, and any concrete CDMO strategy details promised for the next call.

US Business: The Billion-Dollar Trajectory

• Revenue at a 5-year high: Volume growth in inline products and the Mirabegron launch offset anticipated competition in Albuterol and Suprep, while low single-digit price erosion in the base portfolio persisted.
• FY26 ambition set at \$1 bn+: Management explicitly guided for US revenue to cross the billion-dollar mark next fiscal year, with Tolvaptan carrying the first half and injectables ramping in the second.
• Spiriva share is climbing fast: TRx share reached the high 30s (38%) and NRx crossed 40% in January, driven by co-pay programs, Medicare/Medicaid contracting, and conversion efforts, with a stated target of 40%+ overall share.
• Mirabegron assumption bakes in competition: Management assumes additional competition arrives in H2 FY26, making Tolvaptan and injectables the critical offsets for sustaining growth.
• Specialty is the third arm: The ambition is to build a specialty business as a major global pillar, with the US as the primary focus, targeting on-market assets like Xopenex and compelling late-stage opportunities.

Vinita Gupta: "We expect in fiscal year '26, the US should be at a USD billion plus and then look at how we can sustain the growth from there."

Margin & Cost Structure

• EBITDA margins hit a 5-year high of 24.3%: The 334 bps gross margin improvement on a 9M basis came from a better product mix, lower input costs, a reduced share of in-licensed products, higher volumes, and cost efficiencies.
• FY25 margin guidance tightened to 23–23.5%: Management expressed confidence in maintaining growth momentum within this band, even as R&D spend is set to spike in Q4.
• Adjacencies are a near-term headwind: Losses from newer businesses are costing roughly two percentage points of margin, but the expectation is for these to turn positive over the next three years, supporting an upward EBITDA trajectory into FY27–28.
• R&D spend is back-loaded: Full-year R&D is pegged at INR 1,750–1,800 crores, with the majority of Q4 spend tied to five nasal spray filings and injectables.
• Employee and manufacturing costs rose in line with growth: The increase in employee benefit expense reflects annual increments and business expansion, while higher manufacturing costs are linked to volumes and R&D.

India & Branded Markets

• India Formulations grew 9.1% for 9M, ahead of the 8.2% IPM: Key chronic therapies like Diabetes, Cardiac, and GI outpaced the market, and the chronic share of the portfolio increased.
• Respiratory underperformance was a drag: The India respiratory market grew only 4% for nine months, and Lupin grew at 3%, with market focus shifting toward anti-infectives rather than inhalation products. Management expects a bounce-back but offered no specific timeline.
• Diabetes portfolio strengthened via M&A: The acquisition of the Huminsulin range from Eli Lilly and three trademarks from Boehringer Ingelheim bolsters the India diabetes franchise.
• EMEA delivered healthy double-digit growth: EU markets like the UK and Germany were driven by products like Luforbec and NaMuscla, with Luforbec now present in 13 countries and potential launches in Spain and others ahead.
• Emerging markets were mixed: LATAM markets like Brazil and Mexico grew in local currency terms, but reported growth was impacted by FX headwinds.

Pipeline, Launches & Complex Portfolio Shift

• Tolvaptan is the near-term star: Expected to be the major contributor in H1 FY26, with a longer tail than a typical oral solid because it is a specialty REMS product, making conversion slower and the opportunity more durable into FY27.
• Injectables ramp in H2 FY26: The injectables portfolio is expected to scale meaningfully in the second half, complementing Tolvaptan as Mirabegron and Albuterol face additional competition.
• 30+ ANDAs planned over two years, over half complex: The pipeline shift toward complex products is deliberate, aiming to move the portfolio to over 50% complex over the next couple of years.
• Biosimilars strategy is selective and first-wave: Focus is on limited-competition products where Lupin can be one of two or three in the first wave, with Pegfilgrastim, Ranibizumab, Aflibercept, Etanercept (2029), Certolizumab, and Mepolizumab in the pipeline.
• Green propellant is a long-term differentiator: Management expects the MDI market to move materially toward green propellants starting in five years, and Lupin aims to be at the forefront, with product filings expected from FY27 onward.
• Semaglutide is a multi-format play: Oral semaglutide for India is being developed internally, while injectable partnerships are in place for select markets, with a target to be in at least a handful of open markets by calendar year 2027.

Vinita Gupta: "We are very optimistic of our long term growth strategy in the US as it continues to evolve from a commoditized generic business to more complex portfolio of injectables, respiratory and biosimilars, to ultimately a portfolio of strategic specialty assets."

Regulatory, Compliance & Manufacturing

• Clean inspection outcomes stack up: The Pithampur Unit-1 facility received an EIR with VAI classification, and EIRs were received for Aurangabad and Dabhasa, while Somerset and the Nagpur Injectable Facility completed inspections with zero observations.
• Ranibizumab filed in the EU, US filing ahead: The biosimilar was successfully filed in Europe during the quarter, with a US filing expected in the coming quarters.
• Lupin Manufacturing Solutions spun out for CDMO: A dedicated team has been assembled for the CDMO opportunity, with more detail promised on the next call.
• Tariff risk is being actively mitigated: Management is engaging stakeholders with the argument that 70% of US generic drugs are imported and 50% come from India, making critical medicines a poor target for tariffs. Mitigation options include US-based manufacturing where possible.

Vinita Gupta: "70% of generic drugs for the US are imported at present, 50% of generics come from India. So there's clearly a significant role that India plays on the generic front and we've made that case with all the major stakeholders."

Capital Allocation & M&A

• Priority order is India, Specialty, then generics: Capital allocation follows this hierarchy, with India and Specialty as the major focus areas and generics funded only where needed.
• No earmarked investment caps: Spending in India and Specialty is opportunity-driven rather than budget-constrained, and the USD 200–250 million bite-size for acquisitions applies to "several" areas, per management.
• Acquisition environment is favorable: Management sees a rich opportunity set to acquire meaningful assets, particularly in specialty, and is actively evaluating on-market and late-stage assets.

Guidance & Commitments

Key Metrics